Coste del asma en pediatría en España: un modelo de evaluación de costes basado en la prevalencia

Bravo, Aucancela; Pérez-Yarza, E.G.; Mercado, Pablo; Perales, Antonio Bonillo; Vázquez, C.A. Díaz; Moreno‐Galdó, Antonio

doi:10.1016/j.anpedi.2010.10.006

Cited by 36 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The cost of childhood asthma in Spain has been recently assessed in a study by Blasco Bravo et al. (10). They estimated the cost for the management of asthma in children younger than 16 yrs of age during 2008.…”

Section: Costs Of Pediatric Allergymentioning

confidence: 99%

Pediatric allergy and immunology in Spain

Nieto

Mazon

Martín-Mateos

et al. 2011

Pediatric Allergy Immunology

View full text Add to dashboard Cite

The data of the ISAAC project in Spain show a prevalence of childhood asthma ranging from 7.1% to 15.3%, with regional differences; a higher prevalence, 22.6% to 35.8%, is described for rhinitis, and atopic dermatitis is found in 4.1% to 7.6% of children. The prevalence of food allergy is 3%. All children in Spain have the right to be visited in the National Health System. The medical care at the primary level is provided by pediatricians, who have obtained their titles through a 4-yr medical residency training program. The education on pediatric allergy during that period is not compulsory and thus very variable. There are currently 112 certified European pediatric allergists in Spain, who have obtained the accreditation of the European Union of Medical Specialist for proven skills and experience in pediatric allergy. Future specialists in pediatric allergy should obtain their titles through a specific education program to be developed in one of the four accredited training units on pediatric allergy, after obtaining the title on pediatrics. The Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) gathers over 350 pediatric allergists and pediatricians working in this field. SEICAP has a growing activity including yearly congresses, continued education courses, elaboration of technical clinical documents and protocols, education of patients, and collaboration with other scientific societies and associations of patients. The official journal of SEICAP is Allergologia et Immunophatologia, published every 2 months since 1972. The web site of SEICAP, http://www.seicap.es, open since 2004, offers information for professionals and extensive information on pediatric allergic and immunologic disorders for the lay public; the web site is receiving 750 daily visits during 2011. The pediatric allergy units are very active in clinical work, procedures as immunotherapy or induction of oral tolerance in food allergy, contribution to scientific literature, and collaboration in international projects.

show abstract

Section: Costs Of Pediatric Allergymentioning

confidence: 99%

Pediatric allergy and immunology in Spain

Nieto

Mazon

Martín-Mateos

et al. 2011

Pediatric Allergy Immunology

View full text Add to dashboard Cite

show abstract

“…To reduce the cost of childhood asthma should realize interventions in prevention and in the disease management as a very important both the cost and years with persistent asthma is due to preventable causes, such as hospitalizations and care emergency department. [16]…”

Section: Discussionmentioning

confidence: 99%

Cost analysis of childhood asthma in Iran: A cost evaluation based on referral center data for asthma and allergies

et al. 2013

View full text Add to dashboard Cite

Objective:Asthma as the most common chronic disease in childhood reduces the quality of life of children and their families. We aimed to estimate the cost of managing childhood asthma in Iran and to examine its variability depending on asthma severity.Methods:The cost of asthma was estimated by building a cost assessment model regarding the factors that influence the cost of asthma in children including age and sex distribution, prevalence of disease severity, level of resource utilization depending on disease severity (3 groups of controlled, partly controlled and uncontrolled were defined). The model was comprised of both medical (cost of medication, physician visit and respiratory tests) and non-medical (transportation and hoteling) costs. Furthermore, the average family income in each category was figured and the share of asthma managing costs from the average income was calculated in different groups.Findings:According to model, the total cost of childhood asthma in Iran was around 516.5 million dollars. Moreover, direct medical cost represented 49% of the total costs, among which 66% accounting for medication cost. Direct non-medical costs were estimated 51% with the majority (93%) expended on transportation. In addition, the mean annual cost per child was approximately 466 dollars. In addition, the results indicate the vast majority of patients (46%) are categorized in the uncontrolled group.Conclusion:The cost of childhood asthma in Iran is extremely high comparing to the average income of Iranian families in all categories of asthma severity. Considering the high amount of transportation cost, the accessibility of asthma treatment does not appear to be acceptable. The major source of costs is found to be related to medicine expenditure. Since it has been proven that using medicine does not necessarily result in a well-controlled disease status, alternative approaches should be considered in asthma management.

show abstract

“…For children, costs from AOM and LRTI were obtained from official diagnosis‐related groups (DRG) data, taking into account only hospital costs. Asthma total costs were obtained from the published literature 36. In Hungary, total costs due to passive smoking were obtained from an official report on Economic Burden of Smoking in Hungary 22.…”

Section: Methodsmentioning

confidence: 99%

Estimates of costs for modelling return on investment from smoking cessation interventions

Trapero-Bertran

Leidl²,

Muñoz

et al. 2018

Addiction

View full text Add to dashboard Cite

Background and aimsModelling return on investment (ROI) from smoking cessation interventions requires estimates of their costs and benefits. This paper describes a standardized method developed to source both economic costs of tobacco smoking and costs of implementing cessation interventions for a Europe‐wide ROI model [European study on Quantifying Utility of Investment in Protection from Tobacco model (EQUIPTMOD)].DesignFocused search of administrative and published data. A standardized checklist was developed in order to ensure consistency in methods of data collection.Setting and participantsAdult population (15+ years) in Hungary, Netherlands, Germany, Spain and England. For passive smoking‐related costs, child population (0–15 years) was also included.MeasurementsCosts of treating smoking‐attributable diseases; productivity losses due to smoking‐attributable absenteeism; and costs of implementing smoking cessation interventions.FindingsAnnual costs (per case) of treating smoking attributable lung cancer were between €5074 (Hungary) and €52 106 (Germany); coronary heart disease between €1521 (Spain) and €3955 (Netherlands); chronic obstructive pulmonary disease between €1280 (England) and €4199 (Spain); stroke between €1829 (Hungary) and €14 880 (Netherlands). Costs (per recipient) of smoking cessation medications were estimated to be: for standard duration of varenicline between €225 (England) and €465 (Hungary); for bupropion between €25 (Hungary) and €220 (Germany). Costs (per recipient) of providing behavioural support were also wide‐ranging: one‐to‐one behavioural support between €34 (Hungary) and €474 (Netherlands); and group‐based behavioural support between €12 (Hungary) and €257 (Germany). The costs (per recipient) of delivering brief physician advice were: €24 (England); €9 (Germany); €4 (Hungary); €33 (Netherlands); and €27 (Spain).ConclusionsCosts of treating smoking‐attributable diseases as well as the costs of implementing smoking cessation interventions vary substantially across Hungary, Netherlands, Germany, Spain and England. Estimates for the costs of these diseases and interventions can contribute to return on investment estimates in support of national or regional policy decisions.

show abstract

Coste del asma en pediatría en España: un modelo de evaluación de costes basado en la prevalencia

Abstract: The cost of paediatric asthma in Spain is very high and depends on disease severity. Although the most important costs are for the health care system, indirect costs are not negligible.

Cited by 36 publications

References 33 publications

Pediatric allergy and immunology in Spain

Pediatric allergy and immunology in Spain

Cost analysis of childhood asthma in Iran: A cost evaluation based on referral center data for asthma and allergies

Estimates of costs for modelling return on investment from smoking cessation interventions

Contact Info

Product

Resources

About